Company: TAK
Filing Date: 2025-06-27
Form Type: 424B2
Source: 0001628280-25-033198
Chunk: 1

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-27
Form: 424B2
Chunk 1
---
 the date of redemption. See “Description of the Notes and Guarantee—Redemption—Optional Redemption.” In addition, the Issuer may, at its option, redeem a series of the Notes in whole, but not in part, upon the occurrence of certain changes in Japanese tax law. See “Description of Guaranteed Debt Securities—Optional Tax Redemption” in the accompanying prospectus. The Notes will not otherwise be redeemable prior to the stated maturity and will not be subject to any sinking fund.

The Notes will be issued only in registered form in minimum denominations of $200,000 and integral multiples of $1,000 in excess thereof.

Each series of the Notes will be represented by one or more global notes deposited with a custodian for and registered in the name of a nominee of The Depository Trust Company (“DTC”), as depositary. Beneficial interests in the Notes will be shown on, and transfers thereof will be effected only through, records maintained by DTC and its direct and indirect participants, including Euroclear Bank SA/NV (“Euroclear”) and Clearstream Banking S.A. (“Clearstream”).

Investing in the Notes involves risks. You should carefully consider the risk factors set forth in “Item 3. Key Information—D. Risk Factors” of Takeda’s most recent annual report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) and in the “

#### Risk Factors

#### ” section beginning on page

#### S- 7
of this prospectus supplement before making any decision to invest in the Notes.

|                                     |     | Per 2035 Note |        |   |     | Per 2055 Note |        |   |     | Total |               |
|:------------------------------------|:----|:--------------|-------:|:--|:----|:--------------|-------:|:--|:----|:------|--------------:|
| Public offering price(1)            |     |               | 99.644 | % |     |               | 99.734 | % |     | $     | 2,392,131,000 |
| Underwriting discount(2)            |     |               |  0.400 | % |     |               |  0.775 | % |     | $     |    12,412,500 |
| Proceeds, before expenses, to us(1) |     |               | 99.244 | % |     |               |